What Is a PSA Test and When Should You Get One? A Comprehensive Guide

The PSA (Prostate-Specific Antigen) test is the most widely used blood test for evaluating prostate health. It plays a critical role in both prostate cancer screening and the monitoring of prostate enlargement and prostatitis. However, the PSA test is frequently misinterpreted: an elevated PSA does not always mean cancer, and a low PSA does not always mean you are in the clear. In this guide, we cover PSA in all its dimensions.

What Is PSA?

PSA is a glycoprotein produced exclusively by the prostate gland. Its function is to liquefy seminal fluid. Small amounts enter the bloodstream; this value is measured in the blood.

Things that raise PSA:

Prostate enlargement (BPH)
Prostate cancer
Prostatitis (especially acute)
Digital rectal examination
Prostate biopsy
Ejaculation (within 24–48 hours)
Intense cycling
Urinary tract infection
Certain medications (testosterone)

Things that lower PSA:

5-alpha reductase inhibitors (finasteride, dutasteride) — reduce PSA by ~50%; this must be taken into account
Statin use (weak effect)
Obesity (dilution effect)

PSA Normal Values: By Age

PSA values naturally increase with age; therefore, age-specific reference ranges provide a more accurate assessment:

Age	Normal PSA (ng/mL)
40–49	< 2.5
50–59	< 3.5
60–69	< 4.5
70–79	< 6.5

Although a value above 4 ng/mL is generally accepted as “elevated,” this value should be interpreted based on age, prostate volume, and individual risk.

What Does the PSA Value Mean?

PSA (ng/mL)	Interpretation	Approach
< 2.5	Low risk	Routine monitoring
2.5–4	Borderline	Based on age and risk factors; repeat or mpMRI
4–10	Suspicious (“gray zone”)	mpMRI evaluation; biopsy decision
> 10	High suspicion	mpMRI + biopsy strongly indicated

In the “gray zone” (4–10 ng/mL), cancer is detected in approximately 25–35% of cases. This means that in 2 out of 3 men in this group, biopsy comes back negative — a reality that underscores the importance of additional imaging such as mpMRI.

PSA Derivatives: More Precise Assessment

A single PSA value can be insufficient. Additional parameters include:

Free PSA / Total PSA Ratio (f/t PSA)

f/t PSA Ratio	Interpretation
> 25%	Low cancer risk
15–25%	Intermediate risk
< 15%	High cancer risk

In cancer cases, the free PSA ratio decreases; in BPH, it remains elevated.

PSA Density

PSA value / prostate volume (mL)

In men with a large prostate, PSA is naturally higher. PSA density corrects for this:

< 0.10: Low risk
0.10–0.15: Borderline
0.15: High risk; in favor of biopsy

PSA Velocity

An increase of more than 0.75 ng/mL per year raises suspicion for cancer; however, this parameter alone is not sufficient to decide on a biopsy.

PSA Doubling Time

Used in post-treatment follow-up and recurrence assessment. A doubling time of less than 3 months indicates aggressive disease.

What to Watch Out for Before a PSA Test

To avoid inaccurate results:

Situation	Waiting Period
Ejaculation	Wait 48 hours
Digital rectal examination	Wait 48 hours
Cystoscopy / urethral procedure	Wait 1 week
Prostate biopsy	Wait 6 weeks
Active prostatitis / urinary tract infection	After treatment is completed
Intense cycling	Wait 24 hours

The test can be taken in the morning on an empty stomach or after a light breakfast. No special preparation is required.

At What Age Should You Get a PSA Test?

Turkish Urology Association (TUA) Recommendations

Group	Recommendation
Ages 50–70, average risk	Annual PSA + DRE
Age 45+, first-degree family history of prostate cancer	Early start
Age 40+, BRCA2 mutation or strong family history	Early start
Over age 70	Individual decision; continue if life expectancy is 10+ years

The Value of PSA Screening

ERSPC (Europe) study: PSA screening reduced the risk of death from prostate cancer by 21%
PLCO (USA): Organized screening showed no additional benefit over unorganized medical examinations
Conclusion: Informed decision-making is essential; advantages and disadvantages should be discussed with your physician

Next Steps When PSA Is Elevated

Elevated PSA or rapid increase
         ↓
Repeat PSA (4–6 weeks later)
         ↓
Free PSA / Total PSA ratio
         ↓
mpMRI (multiparametric MRI)
         ↓
PI-RADS 1–2: Low suspicion → Monitoring
PI-RADS 3: Clinical decision
PI-RADS 4–5: Biopsy recommended
         ↓
MRI-Fusion or systematic biopsy
         ↓
Gleason / ISUP score

Prostate MRI (mpMRI) and the PI-RADS System

PI-RADS Score	Meaning
1	Cancer extremely unlikely
2	Cancer unlikely
3	Indeterminate
4	Cancer likely
5	Cancer highly likely

MRI-guided biopsy, rather than biopsy before MRI, reduces unnecessary biopsies and better detects clinically significant cancers.

PSA Follow-up Frequency

Baseline PSA	Follow-up Frequency
< 1 ng/mL (ages 50–60)	Every 2–4 years
1–3 ng/mL	Once a year
> 3 ng/mL (< 4 threshold)	Annually or more frequently
> 4 ng/mL	Urology evaluation

Frequently Asked Questions

How is the PSA test performed? It is a simple blood test drawn from the arm, typically in the morning. No special preparation is required, though certain situations (ejaculation, examination, etc.) require waiting a few days.

My PSA came back at 5 ng/mL — do I have cancer? There is a possibility, but it is not certain. When PSA is between 4 and 10, the likelihood of cancer is approximately 25–35%. A definitive diagnosis is reached through mpMRI and, if necessary, biopsy.

Is annual PSA testing necessary? Annual evaluation is recommended for ages 50–70. In men with low PSA values, the interval can be extended to 2–4 years.

My PSA is low — could I still have prostate cancer? Yes. Some aggressive cancers with low differentiation (secreting little PSA) can present with low PSA values. PSA alone is not sufficient; DRE and imaging may also be needed when indicated.

Do I need to fast for a PSA test? No. Fasting does not affect the PSA value. A light breakfast or drinking fluids is not a problem.

How should PSA values be interpreted in men taking finasteride? Finasteride and dutasteride lower PSA by approximately 50%. In men taking these medications, the PSA value should be doubled for interpretation.

Does PSA screening lead to unnecessary biopsies? In the “gray zone” (4–10 ng/mL), approximately 2/3 of biopsies do not detect cancer. The use of mpMRI reduces unnecessary biopsies by 30–50%.

Does PSA screening lower the risk of death? The large European study (ERSPC) showed that PSA screening reduced the risk of death from prostate cancer by 21%. To avoid overtreatment, the active surveillance option can be considered.

Important Note: This content is for general informational purposes only. PSA assessment and screening decisions must always be made together with a urology specialist.